Literature DB >> 31125565

Theophylline induces differentiation and modulates cytoskeleton dynamics and cytokines secretion in human melanoma-initiating cells.

Martina Cordella1, Claudio Tabolacci2, Cinzia Senatore1, Stefania Rossi1, Sabina Mueller3, Carla Lintas4, Adriana Eramo1, Daniela D'Arcangelo5, Salvatore Valitutti6, Antonio Facchiano5, Francesco Facchiano1.   

Abstract

AIMS: Cutaneous melanoma is the most aggressive skin cancer, derived from neoplastic transformation of melanocytes. Since several evidences highlighted the importance of a hierarchical model of differentiation among cancer cells, closely related to resistance mechanisms and tumor relapse, we investigated the effects of theophylline (Theo), a methylxanthine commonly used in treatment of respiratory diseases, on melanoma cells with different degree of differentiation, including patient-derived melanoma-initiating cells.
MATERIALS AND METHODS: The antiproliferative and antimetastatic effects of Theo was demonstrated by cell counting, adhesion and migration assays on A375 and SK-MEL-30 cells. Further, Theo ability to reduce cell growth was highly significant in A375-derived spheroids and in two patient-derived melanoma-initiating cells (MICs). In order to identify pathways potentially involved in the antineoplastic properties of Theo, a comparative mass spectrometry proteomic analysis was used. Then, melanin content, tyrosinase and tissue transglutaminase activities as differentiation markers and actin re-organization through confocal microscopy were evaluated. Furthermore, a secretome profile of MICs after Theo treatments was performed by multiplex immunoassay. KEY
FINDINGS: Obtained results demonstrate inhibitory effects of Theo on melanoma cell proliferation and migration, mainly in MICs, together with the induction of differentiation parameters. Moreover, our data indicate that the known anti-melanoma effect of Theo is due also to its ability to interfere with cytoskeleton dynamics and to induce the secretion of inflammatory molecules involved in recruitment of immunosuppressive cells in tumor microenvironment. SIGNIFICANCE: Data strongly suggest that Theo supplement, either as drug or as dietary supply, may represent a potent additional weapon against melanoma.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Cytokines; Differentiation; Melanoma; Theophylline

Mesh:

Substances:

Year:  2019        PMID: 31125565     DOI: 10.1016/j.lfs.2019.05.050

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches.

Authors:  Claudio Tabolacci; Martina Cordella; Stefania Rossi; Marialaura Bonaccio; Adriana Eramo; Carlo Mischiati; Simone Beninati; Licia Iacoviello; Antonio Facchiano; Francesco Facchiano
Journal:  Molecules       Date:  2021-06-13       Impact factor: 4.411

Review 2.  Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation.

Authors:  Xiaoli He; Yongkang Liao; Jing Liu; Shuming Sun
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

3.  Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals.

Authors:  Claudio Tabolacci; Martina Cordella; Sabrina Mariotti; Stefania Rossi; Cinzia Senatore; Carla Lintas; Lauretta Levati; Daniela D'Arcangelo; Antonio Facchiano; Stefania D'Atri; Roberto Nisini; Francesco Facchiano
Journal:  Biomedicines       Date:  2021-01-15

4.  A noncoding regulatory RNA Gm31932 induces cell cycle arrest and differentiation in melanoma via the miR-344d-3-5p/Prc1 (and Nuf2) axis.

Authors:  Dan Wang; Jianfei Chen; Bohan Li; Qingling Jiang; Ling Liu; Ziyi Xia; Qiusheng Zheng; Minjing Li; Defang Li
Journal:  Cell Death Dis       Date:  2022-04-07       Impact factor: 8.469

5.  Nicotinamide inhibits melanoma in vitro and in vivo.

Authors:  Francesca Scatozza; Federica Moschella; Daniela D'Arcangelo; Stefania Rossi; Claudio Tabolacci; Claudia Giampietri; Enrico Proietti; Francesco Facchiano; Antonio Facchiano
Journal:  J Exp Clin Cancer Res       Date:  2020-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.